Goldman Sachs Just Added UnitedHealth (UNH) to Its Conviction List. Here's Why the Stock Could Soar.

Goldman Sachs added UnitedHealth to its U.S. conviction list, citing an approaching inflection point in Medicare Advantage underwriting and improving Optum margins. UnitedHealth serves more than 7.5 million Medicare Advantage members, reduced its medical cost ratio by 90 bps year over year in Q1 2026, and trades at 20.8x forward earnings versus a 10-year average of 23x. Goldman sees about 12% upside from its price target, supported by stronger earnings growth and elevated market volatility.

Analysis

The setup is less about a single earnings beat and more about a regime shift in earnings quality: if the Medicare Advantage book has truly passed peak bad news, UNH should see operating leverage re-emerge just as the market is paying up for defensive cash flows. That combination matters because the stock’s beta typically falls when investors believe the underwriting cycle has turned, which can create a self-reinforcing multiple expansion even before absolute EPS growth re-accelerates.

The second-order beneficiary is not just UNH, but the broader managed-care complex if investors conclude CMS pricing is no longer a structural headwind. However, UNH’s scale and diversified earnings base likely let it reprice faster than peers, while smaller MA-heavy carriers may still be stuck with narrower pricing flexibility and less ability to shed unprofitable geographies. In other words, the spread between quality leaders and everyone else could widen over the next 2-3 quarters even if the sector as a whole rallies.

The key risk is that the market is front-running an inflection that only shows up cleanly in 2H26 or early 2027, which leaves room for one more negative data point on utilization or mix to interrupt momentum. The other risk is that the ‘defensive’ bid becomes crowded: if volatility falls or growth leadership returns, the valuation support from macro uncertainty can fade quickly. The thesis breaks if medical cost trend re-accelerates faster than pricing catches up, because that would force the market back to a margin-reset narrative.

The contrarian read is that the easy money may already be in the stock after the recent run. At roughly 20.8x forward earnings, the market is no longer pricing UNH like a stressed insurer, so the next leg needs real evidence of margin repair rather than just improved sentiment. That argues for expressing the view with defined risk, not an outright chase at current levels.

Key Decisions for Investors

• Long UNH vs. short the more Medicare-Advantage-sensitive managed-care basket for 3-6 months; use UNH as the quality winner if the underwriting inflection is real, with upside from both EPS revision and multiple expansion.
• Buy UNH call spreads expiring in 6-9 months to express the margin-repair thesis with capped downside; structure around the next two earnings prints, since confirmation likely matters more than the initial re-rating.
• Avoid chasing the stock outright after the recent move; wait for a pullback or for management to confirm accelerating Optum margin improvement before adding size.
• For relative value, rotate out of lower-quality defensive health names into UNH if you want a defensive exposure with operating leverage; the risk/reward is better than owning static yield-like healthcare exposures.
• Set a stop/review trigger if medical cost trends worsen on the next print; if there is no sequential improvement by the next 1-2 quarters, the market may de-rate the stock back toward a low-confidence multiple.